There are 412 resources available
250P - Evolution of characteristics, real-world (rw) treatment (tx) landscape, and survival outcomes in patients (pts) with previously untreated metastatic triple-negative breast cancer (mTNBC) in the United States
Presenter: Kevin Punie
Session: Lunch and Poster Display session
251P - Genomic alterations of breast cancer patients with leptomeningeal disease: A retrospective analysis
Presenter: Louis Larrouquere
Session: Lunch and Poster Display session
252P - Impact of informative censoring on the interpretation of progression-free survival (PFS) estimates in phase III randomized trials (RCT) in metastatic breast cancer (MBC)
Presenter: Yael Berner Wygoda
Session: Lunch and Poster Display session
253P - Patient-centric approach: Examining quality-of-life incorporation in 5-year phase III metastatic breast cancer trials
Presenter: Shreyas Kalantri
Session: Lunch and Poster Display session
254P - Development of machine learning models for the prediction of early progression (EP) to first-line (1L) cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) therapy in oestrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC)
Presenter: Sergio Pannunzio
Session: Lunch and Poster Display session
257P - A low fT3/fT4 ratio as a negative prognostic factor in patients with metastatic breast cancer
Presenter: Paola Zagami
Session: Lunch and Poster Display session
258P - Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France
Presenter: Verena Kiver
Session: Lunch and Poster Display session
259P - Analysis of survival outcomes in breast cancer patients with brain metastases: A comprehensive study utilizing the National Cancer Database
Presenter: Vivek Podder
Session: Lunch and Poster Display session
260P - LUZERN: Phase II trial of niraparib and aromatase inhibitors (AI) for pretreated hormone receptor-positive/HER2-negative germline BRCA-mutated advanced breast cancer
Presenter: Daniel Alcalá-López
Session: Lunch and Poster Display session
261TiP - TROPION-Breast05: Phase (Ph) III study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
Presenter: Peter Schmid
Session: Lunch and Poster Display session